Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8) ELISA Kits

The protein encoded by TNFRSF8 is a member of the TNF-receptor superfamily. Zusätzlich bieten wir Ihnen TNFRSF8 Antikörper (793) und TNFRSF8 Proteine (31) und viele weitere Produktgruppen zu diesem Protein an.

list all ELISA KIts Gen GeneID UniProt
TNFRSF8 943 P28908
TNFRSF8 21941 Q60846
TNFRSF8 25069 P97525
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen
  • orders@antikoerper-online.de

Top TNFRSF8 ELISA Kits auf antikoerper-online.de

Showing 10 out of 43 products:

Katalog Nr. Reaktivität Sensitivität Bereich Bilder Menge Anbieter Lieferzeit Preis Details
Human 3.9 pg/mL 15.6-1000 pg/mL Typical standard curve 96 Tests Anmelden zum Anzeigen 13 bis 16 Tage
$910.56
Details
Maus < 10 pg/mL 10-3000 pg/mL 96 Tests Anmelden zum Anzeigen 2 bis 3 Tage
$673.20
Details
Ratte 0.135 ng/mL 0.31 ng/mL - 20 ng/mL 96 Tests Anmelden zum Anzeigen 13 bis 16 Tage
$800.00
Details
Maus 8 pg/mL 12.3 pg/mL - 3000 pg/mL   96 Tests Anmelden zum Anzeigen 5 bis 8 Tage
$841.92
Details
Ratte < 0.135 ng/mL 0.312 ng/mL - 20 ng/mL   96 Tests Anmelden zum Anzeigen 11 bis 18 Tage
$867.02
Details
Huhn 9.375 ng/mL 15.625 ng/mL - 1000 ng/mL   96 Tests Anmelden zum Anzeigen 11 bis 18 Tage
$724.89
Details
Meerschweinchen 1.875 ng/mL 3.125 ng/mL - 200 ng/mL   96 Tests Anmelden zum Anzeigen 11 bis 18 Tage
$724.89
Details
Affe 0.469 ng/mL 0.781 ng/mL - 50 ng/mL   96 Tests Anmelden zum Anzeigen 11 bis 18 Tage
$724.89
Details
Schwein 0.469 ng/mL 0.781 ng/mL - 50 ng/mL   96 Tests Anmelden zum Anzeigen 11 bis 18 Tage
$724.89
Details
Kaninchen 0.094 ng/mL 0.156 ng/mL - 10 ng/mL   96 Tests Anmelden zum Anzeigen 11 bis 18 Tage
$724.89
Details

Weitere ELISA Kits für TNFRSF8 Interaktionspartner

Human Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8) Interaktionspartner

  1. Data suggest that CD4 (zeige CD4 ELISA Kits)+ T cell-associated HIV-1 RNA is often highly enriched in cells expressing CD30; cells expressing this marker considerably contribute to total pool of transcriptionally active CD4 (zeige CD4 ELISA Kits)+ lymphocytes in individuals on suppressive anti-retroviral drug therapy; CD30 may be a marker of residual, transcriptionally active HIV-1 infected cells in blood and in gut (zeige GUSB ELISA Kits)-associated lymphoid tissue.

  2. The stable elevation in classical Hodgkin lymphoma risk with elevated levels of sCD30 and IL6 (zeige IL6 ELISA Kits) across 4 or more years prior to diagnosis may also reflect a B-cell-stimulatory environment that promotes the genesis of these cancers.

  3. extranodal NK/T-cell lymphoma, nasal type(ENKTL) is the most common type of mature T-cell and NK-cell lymphoma diagnosed at our institution. CD30 is frequently expressed in ENKTL and represents a therapeutic target; however, it may not be a prognostic marker.

  4. This study suggests that in patients with CD30+ lymphoproliferative disorders, an aggressive clinical course cannot be defined by the presence of TP63 rearrangements, as was recently shown in systemic ALK negative anaplastic large cell lymphoma.

  5. Data suggest that Brentuximab Vedotin (SGN-35) damaged CD30 ligand (CD30L (zeige TNFSF8 ELISA Kits))-immune cells through CD30 extracellular vesicles (EVs).

  6. median FoxP3 (zeige FOXP3 ELISA Kits)+ Treg count was higher in CD30+ than in CD30- posttransplant lymphoproliferative disorders, 3.0 vs 0

  7. Variant histology is common in pediatric NLPHL, especially types C and E, which are associated with IgD expression. Type C variant histology and possibly type D are associated with decreased EFS, but neither IgD nor CD30 are adverse features. Variant histology may warrant increased surveillance, but did not affect overall survival.

  8. Expression of CD30 in patients with both DLBCL and other aggressive B-cell lymphomas and the absence of MYC (zeige MYC ELISA Kits) oncogene (zeige RAB1A ELISA Kits)-driven proliferation in the majority of these tumors suggests that brentuximab may be a particularly effective form of targeted therapy in the subset of patients with high CD30 expression.

  9. Prevalence of the CD30 (Ki-1) antigen in human solid tumors was summarized.

  10. CD30 expression was detected in up to 25% of cases of diffuse large B-cell lymphoma and was more frequent in tumors without MYC (zeige MYC ELISA Kits) rearrangement. CD30 expression was not associated with overall survival in R-EPOCH-treated de novo DLBCL patients.

Mouse (Murine) Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8) Interaktionspartner

  1. This study demonstrated the amelioration of MOG35-55 peptide-induced active EAE in CD30 KO mice. CD30 was expressed limitedly on CD4 (zeige CD4 ELISA Kits) T cells at the induction phase of experimental autoimmune encephalomyelitis.

  2. Data indicate that CD30L (zeige TNFSF8 ELISA Kits)/CD30 axis plays a modulatory role in the pathogenesis of experimental autoimmune encephalomyelitis (EAE).

  3. role in the maintenance and activation of IL-17A (zeige IL17A ELISA Kits)-producing gammadelta T cells

  4. These results suggest that CD30 signaling plays an important role in the activation of IL-17A (zeige IL17A ELISA Kits)-producing Vgamma1(-) Vgamma4(-) gammadelta T cells bearing Vgamma6 at an early stage of BCG (zeige SLC11A1 ELISA Kits) infection.

  5. Interference of the CD30-CD30L (zeige TNFSF8 ELISA Kits) pathway reduces atherosclerosis development.

  6. CD30L (zeige TNFSF8 ELISA Kits)/CD30 pathway acts as an accelerator of enteritis in a murine disease model

  7. role of CD30L (zeige TNFSF8 ELISA Kits)/CD30 interactions in allergic rhinitis; results suggest that CD30L (zeige TNFSF8 ELISA Kits) plays an important role in allergic rhinitis

  8. Abrogation of CD30 and OX40 (zeige TNFRSF4 ELISA Kits) signals prevents autoimmune disease in FoxP3 (zeige FOXP3 ELISA Kits)-deficient mice.

  9. Studies demonstrate that CD30L (zeige TNFSF8 ELISA Kits)/CD30 signaling executed by the T-T cell interaction plays a critical role in Th17 cell differentiation.

  10. CD30 can signal in a completely TCR-independent fashion to induce IL-13 (zeige IL13 ELISA Kits) production by effector T cells.

TNFRSF8 Antigen-Profil

Beschreibung des Gens

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.

Genbezeichner und Symbole assoziert mit TNFRSF8

  • TNF receptor superfamily member 8 (TNFRSF8) Antikörper
  • tumor necrosis factor receptor superfamily, member 8 (Tnfrsf8) Antikörper
  • TNF receptor superfamily member 8 (Tnfrsf8) Antikörper
  • Cd30 Antikörper
  • D1S166E Antikörper
  • Ki Antikörper
  • Ki-1 Antikörper
  • TNFRSF8 Antikörper

Bezeichner auf Proteinebene für TNFRSF8

CD30L receptor , Ki-1 antigen , cytokine receptor CD30 , lymphocyte activation antigen CD30 , tumor necrosis factor receptor superfamily member 8 , Tumor necrosis factor superfamily member 8 , tumor necrosis factor superfamily, member CD30 , tumor necrosis factor receptor superfamily, member 8 , tumor necrosis factor receptor superfamily member 8-like

GENE ID SPEZIES
943 Homo sapiens
21941 Mus musculus
25069 Rattus norvegicus
395090 Gallus gallus
457960 Pan troglodytes
487438 Canis lupus familiaris
614780 Bos taurus
722773 Macaca mulatta
100385465 Callithrix jacchus
100579424 Nomascus leucogenys
Ausgewählte Anbieter für TNFRSF8 (TNFRSF8) ELISA Kits
Haben Sie etwas anderes gesucht?